Equities research analysts at Litchfield Hills Research assumed coverage on shares of DarioHealth (NASDAQ:DRIO – Get Free Report) in a research report issued on Monday,Benzinga reports. The brokerage set a “buy” rating and a $3.00 price target on the stock. Litchfield Hills Research’s price target suggests a potential upside of 351.81% from the company’s previous close.
Several other analysts have also commented on DRIO. Stifel Nicolaus dropped their price target on shares of DarioHealth from $3.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. TD Cowen downgraded shares of DarioHealth from a “buy” rating to a “hold” rating and reduced their target price for the stock from $2.00 to $1.00 in a research note on Wednesday, January 29th.
Read Our Latest Report on DarioHealth
DarioHealth Price Performance
DarioHealth (NASDAQ:DRIO – Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). DarioHealth had a negative net margin of 205.62% and a negative return on equity of 72.16%. The company had revenue of $6.75 million during the quarter, compared to analysts’ expectations of $7.48 million. During the same period last year, the firm earned $0.05 earnings per share. On average, research analysts anticipate that DarioHealth will post -1.18 earnings per share for the current year.
Hedge Funds Weigh In On DarioHealth
A hedge fund recently bought a new stake in DarioHealth stock. AMH Equity Ltd acquired a new position in shares of DarioHealth Corp. (NASDAQ:DRIO – Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 250,000 shares of the company’s stock, valued at approximately $153,000. AMH Equity Ltd owned 0.60% of DarioHealth at the end of the most recent reporting period. 33.39% of the stock is currently owned by institutional investors.
DarioHealth Company Profile
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Read More
- Five stocks we like better than DarioHealth
- Should You Invest in Penny Stocks?
- Sprouts Stock: Insider Sales, But Strong Bullish Signals
- What is the NASDAQ Stock Exchange?
- Buffett’s Latest Portfolio Moves, and Another Secret Stock
- 3 Warren Buffett Stocks to Buy Now
- NVIDIA’s NVLink Fusion Ups the Ante for AI Infrastructure
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.